Known targets — ChEMBL curated mechanism
HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9
The experimentally established mechanism targets of Belinostat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 known ✓ | Q13547 | 20/20 | 1.00 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 19/20 | 1.00 |
| ▸ | HDAC3 known ✓ | O15379 | 17/20 | 1.00 |
| ▸ | HDAC4 known ✓ | P56524 | 17/20 | 1.00 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 17/20 | 1.00 |
| ▸ | HDAC2 known ✓ | Q92769 | 17/20 | 1.00 |
| ▸ | HDAC10 known ✓ | Q969S8 | 17/20 | 1.00 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 17/20 | 1.00 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 17/20 | 1.00 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 17/20 | 1.00 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 17/20 | 1.00 |
| ▸ | BRD4 | O60885 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 1/20 | 1.00 |
| ▸ | HTR6 | P50406 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | ASPH | Q12797 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Belinostat SCHEMBL29712104 | 1.00 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| Belinostat SCHEMBL375906 | 1.00 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| Belinostat SCHEMBL29379950 | 1.00 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL1403368 | 0.93 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL1403370 | 0.93 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL1403252 | 0.92 | HDAC8 (1.00) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL1403249 | 0.92 | HDAC8 (1.00) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL13762589 | 0.90 | HDAC1 (0.81) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL12808803 | 0.90 | HDAC1 (0.81) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL13762584 | 0.89 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364089-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH EXCESS FIBRIN DEPOSITION AND/OR THROMBUS FORMATION | CERENO SCIENT AB (SE) | 2023-11-16 | — | — | US | claimed |
| US-11554123-B2 | Compositions and methods for reactivating latent HIV-1 infections | SAINT JOSEPH'S UNIVERSITY (US) | 2023-01-17 | — | — | US | claimed |
| US-10813919-B2 | Use of histone deacetylase inhibitors for enhancing immunotherapies | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-10-27 | — | — | US | claimed |
| US-20200016168-A1 | COMPOSITIONS AND METHODS FOR REACTIVATING LATENT HIV-1 INFECTIONS | SAINT JOSEPH'S UNIVERSITY | 2020-01-16 | — | — | US | claimed |
| US-20190030011-A1 | USE OF HISTONE DEACETYLASE INHIBITORS FOR ENHANCING IMMUNOTHERAPIES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2019-01-31 | — | — | US | claimed |
| WO-2018160676-A1 | COMPOSITIONS AND METHODS FOR REACTIVATING LATENT HIV-1 INFECTIONS | UNIVERSITY OF THE SCIENCES (US) | 2018-09-07 | — | — | WO | claimed |
| WO-2017175010-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH EXCESS FIBRIN DEPOSITION AND/OR THROMBUS FORMATION | CERENO SCIENTIFIC AB (SE) | 2017-10-12 | — | — | WO | claimed |
| US-20170231931-A1 | PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2017-08-17 | — | — | US | claimed |
| EP-3185903-A1 | PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES | Fundación para la Investigación Médica Aplicada (ES) | 2017-07-05 | — | — | EP | claimed |
| US-9669036-B2 | Modulation of reactivation of a latent virus | THE UNIVERSITY OF CHICAGO (US) | 2017-06-06 | — | — | US | claimed |
| US-20110275696-A1 | Thioxanthone-Based Autophagy Inhibitor Therapies to Treat Cancer | SPECTRUM PHARMACEUTICALS, INC. | 2011-11-10 | — | — | US | claimed |
| WO-2011112623-A1 | THIOXANTHONE-BASED AUTOPHAGY INHIBITOR THERAPIES TO TREAT CANCER | SPECTRUM PHARMACEUTICALS, INC. (US) | 2011-09-15 | — | — | WO | claimed |
| US-20110003777-A1 | Methods of Treatment Employing Prolonged Continuous Infusion of Belinostat | TOPOTARGET A/S (DK) | 2011-01-06 | — | — | US | claimed |
| EP-2262493-A1 | METHODS OF TREATMENT EMPLOYING PROLONGED CONTINUOUS INFUSION OF BELINOSTAT | Topotarget A/S (DK) | 2010-12-22 | — | — | EP | claimed |
| WO-2009109861-A1 | METHODS OF TREATMENT EMPLOYING PROLONGED CONTINUOUS INFUSION OF BELINOSTAT | TOPOTARGET A/S (DK) | 2009-09-11 | — | — | WO | claimed |
| WO-2008090534-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF EXCESSIVE WEIGHT GAIN, REDUCTION OF INAPPROPRIATE EATING BEHAVIOURS AND INHIBITION OF BINGE EATING FOR THE TREATMENT OF OBESITY | BERAND LIMITED (IE) | 2008-07-31 | — | — | WO | claimed |
| US-20080119424-A1 | Combined Use of Prame Inhibitors and Hdac Inhibitors | BERNARDS RENE | 2008-05-22 | — | — | US | claimed |
| WO-2007049262-A1 | Methods and compositions for the promotion of neuronal growth and the treatment of asociality and affective disorders | BERAND LIMITED (IE) | 2007-05-03 | — | — | WO | claimed |
| EP-1711210-A2 | COMBINED USE OF PRAME INHIBITORS AND HDAC INHIBITORS | Vereniging Het Nederlands Kanker Instituut (NL) | 2006-10-18 | — | — | EP | claimed |
| WO-2005074995-A2 | COMBINED USE OF PRAME INHIBITORS AND HDAC INHIBITORS | VERENIGING HET NEDERLANDS KANKER INSTITUUT (NL) | 2005-08-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170231931-A1 | PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES | SNCA, PSEN2, PSEN1 | HDAC1 3531/4885HDAC8 4056/4885HDAC3 3869/4885 |
| US-20230364089-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH EXCESS FIBRIN DEPOSITION AND/OR THROMBUS FORMATION | HDAC3, HDAC1, HDAC5 | HDAC1 2/4885HDAC8 9/4885HDAC3 1/4885 |
| US-20110003777-A1 | Methods of Treatment Employing Prolonged Continuous Infusion of Belinostat | HDAC4, HDAC5, HDAC8 | HDAC1 8/4885HDAC8 3/4885HDAC3 9/4885 |
| US-20110275696-A1 | Thioxanthone-Based Autophagy Inhibitor Therapies to Treat Cancer | ATG7, BECN1, SQSTM1 | HDAC1 464/4885HDAC8 414/4885HDAC3 418/4885 |
| US-20080119424-A1 | Combined Use of Prame Inhibitors and Hdac Inhibitors | HDAC5, HDAC8, HDAC11 | HDAC1 7/4885HDAC8 2/4885HDAC3 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.